质子放疗增强靶向间皮素的 CAR-T 细胞治疗在胰腺癌中的疗效

Proton radiation boosts the efficacy of mesothelin-targeting chimeric antigen receptor T cell therapy in pancreatic cancer.

工程化靶向近膜区的抗间皮素 CAR-T 细胞：一种可抵抗脱落抗原的新型结合分子以增强对卵巢癌和胰腺癌的疗效

Engineering a juxtamembrane-targeting CAR T-cell against mesothelin: a novel binder resilient to shed antigen for enhanced efficacy against ovarian an

携带 IL-12 的溶瘤 HSV-2 增强 CAR-T 细胞在异种移植模型中对胰腺癌的疗效

IL-12-armed oncolytic HSV-2 enhances CAR T cell efficacy against pancreatic cancer in xenografted models.

这种协同策略以降低的 CAR-T 剂量实现了持久而强效的肿瘤清除，为胰腺癌及其他具有挑战性的实体恶性肿瘤提供了一种变革性策略。

NKT 细胞和 γδ T 细胞在靶向间皮素的胰腺癌免疫治疗中的疗效

Efficacy of natural killer T and gammadelta T cells in mesothelin-targeted immunotherapy of pancreatic cancer.

表达源自间皮素特异性 scFv 的嵌合抗原受体的 T 细胞在原位人胰腺癌动物模型中的治疗疗效

Therapeutic effiacy of T cells expressing chimeric antigen receptor derived from a mesothelin-specific scFv in orthotopic human pancreatic cancer anim

胰腺癌 CAR-T 细胞耐药的临床与分子解析

Clinical and molecular dissection of CAR T cell resistance in pancreatic cancer.

CAR-T 细胞治疗胰腺癌的进展、挑战与创新策略

Advances, challenges, and innovative strategies of CAR-T cell therapy in pancreatic cancer.

伊布替尼与 PD-1 阻断在胰腺癌临床前模型中增强靶向间皮素的 CAR-T 细胞治疗

Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer.

这些发现确定了用于优化针对 PDAC 的 CAR-T 细胞治疗的临床可操作策略。一项测试 meso-FAP CAR-TEAM T 细胞单独使用或与 ibrutinib 或 PD-1 阻断联合使用的 I 期临床试验正在开发中。

肿瘤顽固，治疗更智能：重新思考胰腺癌 CAR-T

Tumor tough, therapy smarter: Rethinking CAR-T for pancreatic cancer.

胰腺癌新兴嵌合抗原受体免疫细胞治疗：机制、临床进展与未来展望

Emerging Chimeric Antigen Receptor-Immune Cell Therapy for Pancreatic Cancer: Mechanisms, Clinical Advances, and Future Perspectives.